Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California

 

Recent News and Articles on the Keywords: 2006 + [gzip] + web  Related to the article below (Last Update: 8/4/2008)

New mobile browsers bringing real Web to handhelds
Computerworld Kenya, MA - Jul 21, 2008
When activated on both the browser and Web server, Gzip compresses content typically by 75% to 80% on the server before sending it to the browser for ...
Source: Google News

Detecting spam web pages through content analysis -
A Ntoulas, M Najork, M Manasse, D Fetterly - … of the 15th international conference on World Wide Web, 2006 - portal.acm.org
... WWW 2006, May 23?26, 2006, Edinburgh, Scotland ... We measure the redundancy of web pages
by the compression ratio ... We used GZIP [14] to compress pages, a fast and ...

Optimising Web Services Performance with Table Driven XML -
A Ng - Proc. of the 17th Australian Software Engineering Conference, 2006 - doi.ieeecomputersociety.org
... and write data with the gZip [17] compression ... different challenges faced by the Web
Services protocol ... Proceedings of the 2006 Australian Software Engineering ...

TeCaS: A Template Caching System for Dynamic Web Pages -
J Ma, Z Gu - Telecommunications, 2006. AICT-ICIW'06. International …, 2006 - doi.ieeecomputersociety.org
... on Internet and Web Applications and Services (AICT/ICIW 2006) 0-7695-2522-9/06
$20.00 ? 2006 IEEE Page 2. algorithm, the compression algorithm used is gzip [6 ...

A block-sorting lossless data compression algorithm -
M Burrows, DJ Wheeler - SRC Research Report, 1994 - webreview.com
... Media Launches New Dr. Dobb's Journal SD West 2006 announces this ... The document is
a gzip'd PostScript file ... of their papers are available online at this web site ...

Beam dynamics in Compton ring gamma sources
K NSC KIPT - Phys Rev STAB - prst-ab.aps.org
... Download: PDF (1207 kB) , One-column PDF (1232 kB), or gzip'ed PS (659 kB). ... B. Barish,
in EPAC 2006, Edinburgh, Scotland, 2006, http://accelconf.web.cern.ch ...

[PDF] Optimizing Web Service Messaging Performance Using a Context Store for Static Data -
S Oh, MS Aktas, M Pierce, GC Fox, C Authors - Invited paper for 5th WSEAS Int. Conf. on TELECOMMUNICATIONS …, 2006 - wseas.us
... Informatics, Istanbul, Turkey, May 27-29, 2006 (pp334-342) ... alternative, such as Sun's
Fast Web Services [11 ... than conventional compression utilities like GZip [18 ...

[PDF] Global Document Frequency Estimation in Peer-to-Peer Web Search -
M Bender, S Michel, P Triantafillou, G Weikum - … International Workshop on the Web & Databases (WebDB 2006), …, 2006 - db.ucsd.edu
... and Databases (WebDB 2006), June 30, 2006, Chicago, Illinois ... kilobytes per peer per
hour (no gzip compres- sion ... this experiment we use real-world Web data from ...

[PDF] WEB SERVICE ARCHITECTURE FOR MOBILE COMPUTING
S Oh - 2006 - grids.ucs.indiana.edu
Page 1. WEB SERVICE ARCHITECTURE FOR MOBILE COMPUTING ... for the degree Doctor of
Philosophy in the Department of Computer Science, Indiana University August 2006 ...

-
V Lakshmanan, CT Crisan, B Ekambaram, EV Anikin - US Patent 7,051,318, 2006 - Google Patents
... US Patent May 23, 2006 Sheet 2 of 2 ... ture for building OLA memory modules, such as
a web ... dir ' ; Vusr/local/bin/gzip Stech_S { dpcmlibname} .tar ' ; ###bin/ln ...

Virtual reality design techniques for web-based historical reconstructions -
K Badni - Virtual Reality, 2006 - Springer
... [Online]. Available: http://www.gzip.org/ [2005, May 13] Hartman J, Wernecke J
(1996) The VRML2.0 Handbook, building moving worlds on the Web. ...

Source: Google Scholar
 
 

Patients' Own Stem Cells Used In One-Off Treatment To Stop Back Pain

Article Date: 03 Dec 2006 - 20:00pm (PST)

A University of Manchester researcher has developed a treatment for lower back pain using the patient's own stem cells, which could replace the use of strong painkillers or surgery that can cause debilitation, neither of which addresses the underlying cause.

Dr Stephen Richardson, of the University's Division of Regenerative Medicine in the School of Medicine (FMHS), has developed the treatment; and in collaboration with German biotechnology company Arthrokinetics and internationally-renowned spinal surgeons Spinal Foundation are hoping to enter pre-clinical trials next year. It is expected to rapidly yield a marketable product which will revolutionise treatment of long-term low back pain.

As a result Dr Richardson has been named Northwest Young Biotechnologist of the Year (sponsored by Nature) at the North West Development Agency/Bionow awards.

Low back pain (LBP) affects a large proportion of the adult population at some point in their lives and in many of these cases it is persistent, eventually leading to debilitating pain. The majority of the cases of LBP are due to degeneration of the intervertebral disc (IVD), the soft tissue which separates the vertebrae in the spine and protects them from damage; it is the flexibility of this tissue that allows movement of the spine (bending, twisting etc). The IVD is comprised of a central gel-like tissue (nucleus pulposus or NP), surrounded by a fibrous ring of tissue (annulus fibrosus or AF). Over time the NP becomes dry and fibrous and cannot support the weight of the body, which means the disc becomes damaged and painful and this is the source of the LBP in many people.

Article continues below and (thank you)
 
Currently, treatments address the symptoms - mainly pain -using a combination of painkillers, physiotherapy or surgery, removing tissue to relieve the pain or fusing the vertebrae above and below the painful disc level together to remove the pain, although this also stops movement at that disc level. None of these options is ideal as they only treat the symptoms, not the cause, and are of limited long-term success.

The treatment Dr Richardson is developing uses a cell-based tissue engineering approach to regenerate the IVD at the affected level. This is achieved through the combination of the patients' own mesenchymal stem cells (MSCs) and a naturally occurring collagen gel that can be implanted through a minimally-invasive surgical technique.

MSCs are a population of progenitor cells found in the bone marrow of adults which can differentiate into many different cell types in the body, including bone, cartilage, fat and muscle cells. Dr Richardson found that for several reasons he could not use cells from the IVD itself and thus spent a number of years developing a method of producing NP cells from MSCs. He, together with colleagues, now has an international patent on this method. It was the development of this method, combined with the establishment of collaborative links with a company to supply the gel and a surgeon to develop the implantation technique, which won Dr Richardson the award.

Dr Richardson explained: "Once we have extracted the bone marrow from the patient and have purified the MSCs, they will be grown in culture and our patented method of differentiation will be applied. They will then be embedded within a gel which can be implanted back into the patient through an arthroscope.

"The gel used, produced by Arthrokinetics, is based on a collagen that is a component of many tissues within the body, a totally natural product that is similar to the gel already used clinically for the treatment of articular cartilage defects. The ability to reimplant this within the body with an arthroscopic procedure - similar to an endoscopy, in which a camera is inserted through a narrow tube into the body - means that there is only a very small scar on the back and the patient could hopefully return home on the same day or the day after the surgery. Once implanted the differentiated MSCs would produce a new NP tissue with the same properties as the original and would both treat the underlying cause of the disease and remove the painful symptoms."

The treatment has massive implications for the future of LBP treatment -with substantial NHS cost savings as patients could be treated quickly and effectively without any need for extended hospitalisation. In addition, as both the cause and the symptoms are treated, only one treatment should be needed in a lifetime and there would be no need for continuous treatments with painkillers and physiotherapy. The patient would therefore benefit and there are also implications for productivity in the workplace as a large number of work hours are lost every year due to sickness leave for low back pain. In the UK alone the combined figures for lost productivity and health-care costs due to low back pain run in the tens of millions of pounds a year and this will only increase as the population ages.

Dr Richardson said: "I am delighted to have won the award. The judges acknowledged the importance of the work and the advances we had made in the treatment strategy. In particular they noted that with all the hype surrounding MSC-based treatments of many diseases, the fact that we were hoping to start pre-clinical trials next year was a massive step towards finally realising the potential of MSCs in a clinical environment.

"They also commented on the difficulties I had overcome in finding an appropriate gel to complement the MSC differentiation work and in drawing in both commercial interest from the company which produces the gel and clinical interest from spinal surgeons who saw the potential of the treatment."

Dr Judith Hoyland, head of the Intervertebral Disc Regeneration and Spinal Disease research group, said: "Dr Richardson has strived hard to overcome the numerous hurdles involved in such a complex process. As a result of his tireless dedication to the development of a clinically-viable tissue engineering strategy for treatment of low back pain, he was the ideal candidate to receive the young biotechnologist of the year award. I hope that it will spur him on to develop his full potential as a biotechnologist and become a credit to the burgeoning Northwest biotechnology sector." ###


 
The University of Manchester (http://www.manchester.ac.uk/) is the largest higher education institution in the country, with 24 academic schools and over 36,000 students. Its Faculty of Medical & Human Sciences (http://www.mhs.manchester.ac.uk/) is one of the largest faculties of clinical and health sciences in Europe, with a research income of around 51 million pounds (almost a third of the University's total research income). The Faculty is a key stakeholder in the Greater Manchester Research Alliance, is affliated to five teaching hospitals and closely linked to general hospitals and community practices across the North West of England. The Division of Regenerative Medicine has the highest number of PhD students to active researchers in the School and its key objectives are increasing research funding from external sources, increasing publications and attracting more taught and research postgraduate students. It also aims to increase research outputs in tissue regeneration and to develop translational research. The Northwest Development Agency (NWDA) is responsible for the sustainable economic development and regeneration of England's Northwest and has 5 key priorities: Business Development, Regeneration, Skills & Employment, Infrastructure and Image. The annual Northwest Biotechnology Awards is organized by Bionow, the NWDA's cluster support organization, to showcase the very best of biotechnology in the region.

Contact: Mikaela Sitford
University of Manchester
 
Google
Web www.iconocast.com
 
 
 

 

Continue News With:News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services. Home

 
 © 2002-2006

Keywords::

Contact Iconocast

Home Page